FDA Inspection 1285748 — Hikma Pharmaceuticals USA INC.

Hikma Pharmaceuticals USA INC. — FEI 1510690

The FDA completed an inspection of Hikma Pharmaceuticals USA INC. on Sep 18, 2026 in Columbus, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Sep 18, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Columbus, OH (United States)

Additional details

Risk Evaluation and Mitigation Strategies (REMS)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.